MEI Pharma Inc (FRA:MMI0)
€ 4.2 0 (0%) Market Cap: 29.12 Mil Enterprise Value: -15.19 Mil PE Ratio: 1.14 PB Ratio: 0.61 GF Score: 46/100

MEI Pharma Inc Investor and Analyst Event - A New Chapter in PI3Kd Inhibition to Treat B-cell Malignancies Transcript

Oct 04, 2019 / 12:00PM GMT
Release Date Price: €37.4 (+24.67%)
Daniel P. Gold
MEI Pharma, Inc. - CEO, President & Director

So thank you all for attending this morning. It's great to see you all. This is our Investor Analyst Day for MEI Pharma, in case you're not in the right room. Before we get started, we're very excited, I think we have a really interesting program I hope you all appreciate. And we'll be giving you an update on our lead programs. Just a few housekeeping -- just to keep the flow. It's a very long day, we know that you're all very busy. We'll try and keep everything on schedule.

If you do have any questions, we're going to try and hold them to the end, and there'll be a couple of microphones that will passed around. If for any reason you have a burning question and you can't stay till the end, just pass it to a friend next to you or give it to David Walsey, who I'm sure you all know, he's the one that badgers you all the time. And he can ask a question at the Q&A.

So there's the obligatory forward-looking statement slide. We will have forward-looking statements, and I invite you to go our SEC filings that can be found on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot